Code of Ethics

Mission-Driven Neutrality

Americans for Ibogaine (AFI) is a nonprofit organization committed to advancing the medicalization of ibogaine in the United States. AFI’s goal is to help establish the medicalization of ibogaine in the United States—specifically, the successful completion of Phase 3 clinical trials and, ultimately, FDA approval. Our goal is to make ibogaine available domestically under medical supervision and with insurance coverage.

We pursue this mission through four core pillars: education, advocacy, community engagement, and strategic initiatives. Our goal is to share accurate, evidence-based information while elevating the voices of those who have undergone ibogaine treatment. Together, science and lived experience help build public understanding of ibogaine’s therapeutic potential.

AFI is a nonpartisan organization. We do not support or oppose candidates or political parties as an organization. Our advocacy is issue-based, data-informed, and designed to benefit all people—not partisan agendas.

AFI does not operate ibogaine clinics, provide treatment, or offer medical advice in the capacity of a healthcare provider. We understand that, in the absence of domestic access, many people are exploring ibogaine treatment options internationally—and we believe this underscores the urgency of establishing a safe, legal pathway for care in the United States.

We do not endorse or promote specific ibogaine providers. In some cases, when members of our team have personally visited a clinic, we may share that information upon request for the purpose of general education only and clarify that we felt comfortable with their practices at the time. We are open to visiting and learning about other clinics outside the United States as part of our ongoing effort to better understand the global treatment landscape. However, AFI does not assume responsibility for any individual experience, medical outcome, or business practice of any clinic, provider, or treatment facility. We strongly encourage individuals to conduct their own research, consult medical professionals, and make informed decisions.

This principle of neutrality also extends to our engagement with the broader ecosystem—including research institutions, biotech companies, advocacy groups, and responses to government-issued RFPs. While AFI does not endorse specific entities, we aim to elevate credible science, responsible innovation, and individuals or organizations doing meaningful work in this space. Our role is to inform, connect, and support progress—not to control access or shape outcomes for any one group.

Because ibogaine remains a Schedule I substance in the United States, most people seeking treatment are forced to travel abroad—often at significant personal cost and risk. AFI is working to change this reality by advancing the medicalization of ibogaine within the U.S. healthcare system. Our goal is to create a safe, legal, and affordable pathway to care for those who need it most.

Integrity & Transparency

AFI board and staff members hold ourselves to high standards of integrity and transparency. The educational content we share is based on the latest scientific evidence as well as personal experiences with ibogaine. AFI disseminates information in furtherance of the public interest and does not accept money in exchange for media coverage, access, or influence.

We may accept philanthropic support from individuals or entities connected to ibogaine treatment centers, but such support is never conditioned on AFI's promotion, endorsement or preferential treatment of those treatment centers. All donors, conference sponsors, speakers, and partner organizations agree that their contributions will not influence AFI’s educational materials, research and legislative priorities, or public communications.

Board members, staff, and volunteers are expected to disclose potential conflicts of interest and to act in the best interest of the mission. We strive to remain independent, fair, and clear in our mission.

Legislative Advocacy

AFI’s mission is the medicalization of ibogaine in the United States—specifically, the successful completion of Phase 3 clinical trials and, ultimately, FDA approval. Our goal is to make ibogaine available domestically under medical supervision and with insurance coverage.

We work to achieve this through advocacy, education, and community engagement at both the state and federal levels. AFI supports legislation focused on medical use; we do not support decriminalization or broad legalization of ibogaine.

However, when legislation includes provisions for controlled medical access to ibogaine, even if the broader bill falls outside our scope, we believe we have a responsibility to advise. Ensuring safe, ethical, and medically supervised access to this life-saving medicine is central to our mission.

Inclusivity & Respect

AFI is committed to inclusion and belonging. We welcome people of all backgrounds and are intentional about lifting up those whose voices have historically been overlooked or silenced.

We do not discriminate on the basis of:

  • Race or ethnicity

  • National origin or immigration status

  • Gender identity or expression

  • Sexual orientation

  • Religion or belief system

  • Age

  • Political affiliation

  • Military or Veteran status

  • Disability or neurodivergence

  • History of substance use, trauma, or incarceration

We affirm that healing is a human right—and that everyone deserves access to accurate information, compassion, and dignity.

Collaborations

AFI collaborates with a broad network of researchers, families, clinicians, politicians, non-profits, interested organizations, and treatment providers to advance our educational and awareness mission. These collaborations do not imply formal partnerships or endorsements. We are transparent about the nature and limits of our relationships. We believe we are stronger together—but all collaboration must align with AFI’s ethics and values. We reserve the right to end any relationship that falls short of these standards.

Social Media & Content Sharing

AFI may engage with or amplify content from clinics, individuals, or organizations working in the psychedelic space. We do so when the content is informative, educational, or helps raise awareness about the need for research. However, such engagement does not constitute an endorsement of any specific clinic, provider, individual, or treatment model. AFI remains an independent, nonpartisan nonprofit committed to education.

Integration Period After Ibogaine Treatment

It is common for individuals who undergo life-changing treatment with ibogaine to feel compelled to advocate for it. AFI deeply values this passion—personal stories are central to advancing our mission. However, we also recognize that a meaningful integration period is not only ethically essential but also critical for long-term healing and clarity.

AFI requires a minimum of 90 days post-bogaine treatment before engaging in any discussions about potential collaboration, fundraising, and any other form of support for AFI's efforts. We also expect clinicians, individuals, and organizations who collaborate with AFI to uphold similar standards. Ibogaine and its metabolite, noribogaine, have lasting physiological and psychological effects that necessitate time for reflection, stabilization, and integration.

This policy ensures that individuals are given the space to fully process their experience and can offer support from a place of informed consent and personal readiness. It is in the best interest of the individual, the clinics, and the integrity of AFI’s work.

Lived Experience & Ethical Storytelling

AFI relies on lived experience and personal testimony as a cornerstone of our education and awareness efforts. We honor the individuals who choose to share their stories by obtaining informed consent, offering the option for anonymity, and prioritizing dignity, accuracy, and respect. We believe these stories offer essential insight into ibogaine’s potential, and we are committed to presenting them in a way that is honest, balanced, and never misleading.

We also strive to be transparent about the risks. We believe public education must include open, fair discussion of the potential for destabilization, adverse reactions, and the medical complexities involved in ibogaine treatment—especially for vulnerable populations.

Commitment to Growth & Accountability

We view ethics as a living commitment, not a static policy. We actively seek feedback, pursue ongoing learning, and remain accountable to the communities we serve. As science evolves and access expands, so too will our standards and practices.